Literature DB >> 26811236

Use of an Acetyl Derivative to Improve GC-MS Determination of Norbuprenorphine in the Presence of High Concentrations of Buprenorphine in Urine.

Joel R Gervais1, Gregory A Hobbs2.   

Abstract

Certain patients being treated with Suboxone™ or Subutex™ can exhibit very high buprenorphine and low norbuprenorphine concentrations in urine. Very high buprenorphine can interfere with buprenorphine-D4 used as an internal standard, causing errors in norbuprenorphine determination by gas chromatography-mass spectrometry (GC-MS). We used a modified method of Wu et al. to introduce norbuprenorphine-D3 as a separate internal standard for norbuprenorphine. This allowed us to accurately measure norbuprenorphine in neat urine specimens when buprenorphine is present in extremely high concentrations. Laboratories measuring buprenorphine and metabolite by GC-MS may face this problem if their clientele includes patients being treated with other medications that interfere with the cytochrome p450 CYP 3A4-mediated conversion of buprenorphine to norbuprenorphine.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26811236      PMCID: PMC4885923          DOI: 10.1093/jat/bkw001

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  18 in total

1.  The development and application of a rapid gas chromatography-mass spectrometry method to monitor buprenorphine withdrawal protocols.

Authors:  S George; C George; M Chauhan
Journal:  Forensic Sci Int       Date:  2004-07-16       Impact factor: 2.395

2.  Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir.

Authors:  R Douglas Bruce; Frederick L Altice
Journal:  AIDS       Date:  2006-03-21       Impact factor: 4.177

3.  Evaluation of various derivatization approaches for gas chromatography-mass spectrometry analysis of buprenorphine and norbuprenorphine.

Authors:  Chih-Hung Wu; Shu-Ching Yang; Yu-Shan Wang; Bud-Gen Chen; Ching-Chiang Lin; Ray H Liu
Journal:  J Chromatogr A       Date:  2007-11-28       Impact factor: 4.759

4.  Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes.

Authors:  C Iribarne; D Picart; Y Dréano; J P Bail; F Berthou
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

5.  Development and validation of a sensitive analytical method for the simultaneous determination of buprenorphine and norbuprenorphine in human plasma.

Authors:  S Gopal; T B Tzeng; A Cowan
Journal:  Eur J Pharm Biopharm       Date:  2001-03       Impact factor: 5.571

6.  Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.

Authors:  C Iribarne; F Berthou; D Carlhant; Y Dreano; D Picart; F Lohezic; C Riche
Journal:  Drug Metab Dispos       Date:  1998-03       Impact factor: 3.922

7.  Development and validation of a highly sensitive GC/MS method for the determination of buprenorphine and nor-buprenorphine in blood.

Authors:  Ioannis I Papoutsis; Panagiota D Nikolaou; Sotirios A Athanaselis; Constantinos M Pistos; Chara A Spiliopoulou; Constantinos P Maravelias
Journal:  J Pharm Biomed Anal       Date:  2011-02-20       Impact factor: 3.935

Review 8.  Clinical efficacy of buprenorphine: comparisons to methadone and placebo.

Authors:  Walter Ling; Donald R Wesson
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

9.  The metabolism and excretion of buprenorphine in humans.

Authors:  E J Cone; C W Gorodetzky; D Yousefnejad; W F Buchwald; R E Johnson
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

10.  A simple gas chromatography-mass spectrometry procedure for the simultaneous determination of buprenorphine and norbuprenorphine in human urine.

Authors:  Dwain C Fuller
Journal:  J Anal Toxicol       Date:  2008-10       Impact factor: 3.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.